GlobeNewsWire
10 Apr 2026, 20:02 UTC · 29w ago
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
Verdict
Headline takes no side. We score ALLO −0.20 — slightly bearish.
- Expected · ALLO
−0.20slightly bearish
−1 bearish0bullish +1More negative than 71% of ticker scores this week





